Patient Search
 |
 |
|
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Prostate
Prostate
Prostate
III
Schaffer, Kerry
NCT03678025
SWOGUROS1802
Evaluation of Digoxin for Relapsed non-WNT, non-SHH Medulloblastoma (Phase 2 Study)
Multiple Cancer Types
Neuro-Oncology,
Pediatrics
II
Esbenshade, Adam
NCT06701812
VICCPED24621
ETHAN: A Phase II Study Comparing Different Endocrine Therapies for Male Breast Cancer
Breast
Breast
Breast
II
Sharpe, Jessica
NCT05501704
VICCBRE25028
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Multiple Cancer Types
Bladder,
Kidney (Renal Cell),
Rectal
II
Schaffer, Kerry
NCT03866382
ALLIANCEUROA031702
A Phase 3, Randomized, Open-Label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants with Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery
Breast
Breast
Breast
III
Kennedy, Laura
NCT06393374
VICC-DTBRE23439
A Phase 1/3 Study to Evaluate the Efficacy and Safety of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Ruxolitinib, in Treatment-Nave Patients with Myelofibrosis
Multiple Cancer Types
Hematologic,
Phase I
I/III
Mohan, Sanjay
NCT04562389
VICCHEMP2130
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
Miscellaneous
Miscellaneous
Miscellaneous
I/II
Cardin, Dana
NCT04657068
VICCGIP25035
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants with Myeloproliferative Neoplasms
Not Available
I
Kishtagari, Ashwin
NCT06313593
VICC-DTHEM24055P
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination with Ruxolitinib in Participants with Myeloproliferative Neoplasms
Leukemia
Leukemia
Leukemia
I
Mohan, Sanjay
NCT06034002
VICC-DTHEM23416P
Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
Hematologic
Hematologic
Hematologic
III
Dholaria, Bhagirathbhai
NCT03394365
VICCCTT1875
